Preoperative albumin-bilirubin score is a prognostic factor for gastric cancer patients after curative gastrectomy

Table 1 Clinical and surgical characteristics of patients with gastric cancer according albumin-bilirubin risk groups, n (%)

Variables	Low-ALBI group (< -2.82), n = 211	High-ALBI group (≥ -2.82), n = 150	P value
Sex			0.712
Female	72 (34.1)	54 (36.0)
Male	139 (65.9)	96 (64.0)
Age (yr)			0.005
mean (SD)	62.0 (12.0)	65.6 (12.2)
BMI (kg/cm²)			0.856
mean (SD)	25 (4.5)	25.2 (16.5)
Hemoglobin (g/dL)			< 0.001
mean (SD)	12.7 (2.1)	11.1 (2.1)
Albumin (g/dL)			< 0.001
mean (SD)	4.3 (0.3)	3.5 (0.5)
Bilirubin (mg/dL)			0.072
mean (SD)	0.41 (0.22)	0.47 (0.33)
Neutrophil to lymphocyte ratio			0.092
mean (SD)	2.48 (2.29)	2.91 (2.56)
American Society of Anesthesiologists			0.001
I/II	178 (84.4)	105 (70.0)
III/IV	33 (15.6)	45 (30.0)
Charlson–Deyo Comorbidity Index1			0.344
0	141 (66.8)	93 (62.0)
≥ 1	70 (33.2)	57 (38.0)
Type of gastrectomy			0.562
Subtotal	126 (59.7)	85 (56.7)
Total	85 (40.3)	65 (43.3)
Lymphadenectomy			0.003
D1	34 (16.1)	44 (29.3)
D2	177 (83.9)	106 (70.7)
Preoperative chemotherapy			0.477
No	175 (82.9)	120 (80)
Yes	36 (17.1)	30 (20)

¹Considered without including age and cancer as comorbidity.

P values in bold are statistically significant. BMI: Body mass index; ALBI: Albumin-bilirubin.